Radioimmunotherapy (RIT) is a novel strategy for treating non-Hodgkin lymphoma (NHL). Several studies have shown the promising results of using RIT in NHL, which have led to FDA approval for two RIT agents in treating low grade NHL. In spite of these favorable results in low-grade NHL, most of the aggressive or relapsed/refractory NHL subjects experience relapses following RIT. Although more aggressive treatments such as myeloablative doses of RIT followed by stem cell transplantation appear to be able to provide a longer survival for some patients these approaches are associated with significant treatment-related adverse events and challenging to deliver in most centers. Therefore, it seems reasonable to develop treatment approaches that enhance the efficiency of RIT, while reducing its toxicity. In this paper, novel methods that improve the efficiency of RIT and reduce its toxicity through various mechanisms are reviewed. Further clinical development of these methods could expand the NHL patient groups eligible for receiving RIT, and even extend the use of RIT to new indications and disease groups in future.

放射免疫疗法（RIT）是一种治疗非霍奇金淋巴瘤（NHL）的新策略。多项研究表明，在NHL中使用RIT的结果令人鼓舞，这使得FDA批准了两种RIT药物用于治疗低级NHL。尽管在低级NHL中取得了这些有利的结果，但大多数积极或复发/难治性NHL受试者在RIT后仍会复发。尽管更激进的治疗方法，例如RIT的清髓性剂量再加干细胞移植，似乎能够为某些患者提供更长的生存期，但这些方法都伴随着与治疗相关的重大不良事件，并且在大多数医疗中心面临着挑战。因此，开发能够提高RIT效率同时降低其毒性的治疗方法似乎是合理的。在本文中，本文综述了通过多种机制提高RIT效率并降低RIT毒性的新方法。这些方法的进一步临床开发可以扩大有资格接受RIT的NHL患者组，甚至将来将RIT的应用范围扩展到新的适应症和疾病组。